Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | ADH1A | P07327 | 2/20 | 0.35 |
| ▸ | ADH1C | P00326 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.32 |
| ▸ | NAAA | Q02083 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12430313 | 1.00 | SLC18A3 (0.40) | SLC18A3CYP1A2OPRM1OPRK1OPRD1 | |
| SCHEMBL12510576 | 0.96 | SLC18A3 (0.42) | SLC18A3CYP1A2OPRM1OPRK1OPRD1 | |
| SCHEMBL20087337 | 0.91 | ADH1A (0.40) | SLC18A3CYP1A2OPRM1OPRK1OPRD1 | |
| SCHEMBL24085914 | 0.86 | ADH1A (0.40) | SLC18A3OPRM1OPRK1OPRD1ADH1A | |
| SCHEMBL21159067 | 0.86 | SLC18A3 (0.37) | SLC18A3OPRM1OPRK1OPRD1ADH1A | |
| SCHEMBL26620832 | 0.84 | ADH1A (0.36) | SLC18A3OPRM1OPRK1OPRD1ADH1A | |
| SCHEMBL20091645 | 0.80 | SLC18A3 (0.41) | SLC18A3OPRM1OPRK1OPRD1SIGMAR1 | |
| SCHEMBL17506598 | 0.78 | ADH1A (0.35) | SLC18A3OPRM1OPRK1OPRD1ADH1A | |
| SCHEMBL27010684 | 0.78 | ADH1A (0.32) | SLC18A3ADH1AADH1C | |
| SCHEMBL3373129 | 0.77 | ADH1A (0.42) | CYP1A2ADH1AADH1CSIGMAR1NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7982064-B2 | Method for preparing ortho-substituted aminoferrocenes | BROCK UNIVERSITY (CA) | 2011-07-19 | — | — | US | disclosed |
| US-20100137588-A1 | METHOD FOR PREPARING ORTHO-SUBSTITUTED AMINOFERROCENES | BROCK UNIVERSITY (CA) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137588-A1 | METHOD FOR PREPARING ORTHO-SUBSTITUTED AMINOFERROCENES | LPO, AOC1, AOC2 | SLC18A3 675/4885CYP1A2 1740/4885OPRM1 2407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.